 MENLO PARK, Calif. and BOSTON, March 04, 2021 GLOBE NEWSWIRE -- Adicet Bio, Inc. Nasdaq: ACET, a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Andrew Sinclair, Ph.D., to its board of directors. Dr. Sinclair will replace Erez Chimovits, who will step down from the Board of Directors. 